A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 6, 2006, Pages 809-815

  Ford, Hugo E R ^a   Yap, Yoon Sim ^a   Miles, David W ^b,c   Makris, Andreas ^b   Hall, Marcia ^b   Miller, Liz ^a   Harries, Mark ^c   Smith, Ian E ^a   Johnston, Stephen R D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MOUNT VERNON CANCER CENTRE   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Docetaxel; Metastatic breast cancer; Weekly chemotherapy

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DOCETAXEL; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; EPIPHORA; ERYTHEMATOSQUAMOUS SKIN DISEASE; FACE DISORDER; FATIGUE; FEMALE; FEVER; FOOT DISEASE; HAND FOOT SYNDROME; HAND RASH; HUMAN; HYPERLACRIMATION; INFECTION; LACRIMATION DISORDER; LETHARGY; METASTASIS; NEUROPATHY; NEUTROPENIA; ONYCHOLYSIS; PHASE 2 CLINICAL TRIAL; PLANTAR RASH; PREMEDICATION; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; ALOPECIA; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; SURVIVAL ANALYSIS; TAXOIDS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 33748476262     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0222-9     Document Type: Article

References (46)

1. Ahmadi MA, Esmaeli B (2001) Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 119:1802-1804
2. Aihara T, Kim Y, Takatsuka Y (2002) Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 13:286-292
3. Baselga J, Tabernero JM (2001) Weekly docetaxel in breast cancer: applying clinical data to patient therapy. Oncologist 6(suppl 3):26-29
4. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2:1843-1849
5. Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, Winer EP (2000) Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 18:1212-1219
6. Camps C, Massuti B, Jimenez A, Maestu I, Gomez RG, Isla D, Gonzalez JL, Almenar D, Blasco A, Rosell R, Carrato A, Vinolas N, Batista N, Giron CG, Galan A, Lopez M, Blanco R, Provencio M, Diz P, Felip E (2005) Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Ann Oncol (Epub ahead of print)
7. Chu CY, Yang CH, Yang CY, Hsiao GH, Chiu HC (2000) Fixed erythrodysaesthesia plaque due to intravenous injection of docetaxel. Br J Dermatol 142:808-811
8. D'hondt R, Paridaens R, Wildiers H, Pauwelyn K, Thomas J, Dumez H, Van Oosterom AT (2004) Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study. Anticancer Drugs 15(4):341-346
9. Eniu A, Palmieri F, Perez E (2005) Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10:665-685
10. Esmaeli B, Valero V, Ahmadi MA, Booser D (2001) Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 108:994-995
11. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V (2002) Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 109:1188-1191
12. Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu S, Amir Ahmadi M (2003) Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 98:504-507
13. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808
14. Fumoleau P, Brain E, Delozier T, Asselain B, Serin D, Roche H, Spielmann M, Geneve J, Jimenez M, Bonnetain F (2005) Adjuvant dose-dense (3 FEC100 followed by 3 docetaxel every 2 weeks) regimen is not feasible. Results of the FNCLCC-PACS 06 Study. In: Presented at the 28th annual San Antonio breast cancer symposium, Dec 8-11, 2005. Abstract 2071
15. Gervais R, Ducolone A, Breton JL, Braun D, Lebeau B, Vaylet F, Debieuvre D, Pujol J-L, Tredaniel J, Clouet P, Quoix E (2005) Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC). Ann Oncol 16(1):90-96
16. Grant DS, Williams TL, Zahaczwesky M, Dicker AP (2003) Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104:121-129
17. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, Salvagni S, Piantedosi FV, Palazzolo G, Caffo O, Ceribelli A, Falcone A, Mazzanti P, Brancaccio L, Capuano MA, Isa L, Barbera S, Perrone F, on behalf of the DISTAL (Docetaxel In Second-line Treatment of Advanced Lung cancer) Investigators (2004) A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small cell lung cancer. The DISTAL 01 study. Br J Cancer 91(12):1996-2004
18. Hainsworth JD, Burris HA III, Erland JB, Thomas M, Greco FA (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16:2164-2168
19. Hainsworth JD, Burris HA III, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA (2001) Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 19:3500-3505
20. Haldar S, Basu A, Croce CM (1997) Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233
21. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM (2005) Randomised phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23:5542-5551
22. Kuroi K, Bando H, Saji S, Toi M (2003) Protracted administrationof weekly docetaxel in metastatic breast cancer. Oncol Rep 10:1479-1484
23. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT (1999) Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14:31-36
24. Loeffier, TM, Freund W, Droge C, Hausamen TU (1998) Activity of weekly taxotere in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:113a (abstract 435)
25. Loeffier TM, Droege C, Hausamen TU (1999) Dose dense weekly docetaxel (TAXOTERE® ) in metastatic breast cancer. Breast Cancer Res Treat 57(1):125 (abstract 527)
26. Luck HJ, Donne S, and Glaubitz (1997) Phase I study of weekly docetaxel (taxotere) in heavily pretreated breast cancer patients. Eur J Cancer 33, abstract 703a
27. Maisano R, Mare M, Zavettieri M, Caristi N, Mesiti M, Scisca C, La Torre F (2003) Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer? Anticancer Res 23(2C):1923-1926
28. Maisano R, Mare M, Caristi N, Chiofalo G, Picciotto M, Carboni R, Mafodda A, La Torre F (2005) A modified weekly docetaxel schedule as first-line chemotherapy in elderly metastatic breast cancer: a safety study. J Chemother 17:242-246
29. Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IG (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14(3):233-238
30. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207-214
31. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 17:1413-1424
32. Nagore E, Insa A, Sanmartin O (2000) Antineoplastic therapy-induced palmar plantar erythrodysesthesia ('hand-foot') syndrome. Incidence, recognition and management. Am J Clin Dermatol 1: 225-234
33. Nistico C, Cognetti F, Frontini L, Barni S, Ferretti G, Bria E, Milella M, Garufi C, Cuppone F, Vanni B, Carlini P, Terzoli E (2005) Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study. Oncology 68:356-363
34. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicentre phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223
35. Ramos M, Gonzalez-Ageitos A, Amenedo M, Gonzalez-Quintas A, Gamazo JL, Togores P, Losada G, Almanza C, Romero C, Gomez-Martin C (2003) Weekly docetaxel as second-line therapy for patients with advanced breast cancer resistant to previous anthracycline treatment. J Chemother 15(2):192-197
36. Schuette W, Nagel S, Blankenburg T, Lautenschlaeger C, Hans K, Schmidt EW, Dittrich I, Schweisfurth H, von Weikersthal LF, Raghavachar A, Reissig A, Serke M (2005) Phase III study of second-line chemotherapy for advanced non-small-cell lung cancer with weekly compared with 3-weekly docetaxel. J Clin Oncol 23:8389-95
37. Seidman AD, Berry D, Cirrincione C, Harris L, Dressler L, Muss H, Naughton M, Norton L, Winer E, Hudis C (2004) CALGB 9840: phase III study of weekly paclitaxel via 1-hour infusion versus standard 3-hour infusion every three weeks in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomised for T in HER2 normal MBC (abstract). Proc Am Soc Clin Oncol 23:6s
38. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, Moynahan ME, Theodolou M, Golub M, Baselga J, Norton L (1998) Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361
39. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
40. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE (2005) Phase III study of doxorubicin- cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: results of North American Breast Cancer Intergroup Trial E1199 (abstract). In: Presented at the 28th annual San Antonio breast cancer symposium, Dec 8-11, 2005
41. Spazzapan S, Crivellari D, Lombardi D, Scuderi C, Magri MD, Veronesi A, Gatti A, Perez EA (2002) Nail toxicity related to weekly taxanes: an important issue requiring a change in common toxicity criteria grading?. J Clin Oncol 20:4404-4405
42. Stemmler J, Mair W, Stauch M, Papke J, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, Jackisch C, Leinung S, Brudler O, Vehling-Kaiser U, Stamp J, Heinemann V (2005) High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer. Oncology 68(1):71-78
43. Taberno J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL, Baselga J (2004) A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15:1358-1365
44. Tannock IF, de Wit R, Berry WR, Hort J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, for the TAX 327 Investigators et al (2004) Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 351(15):1502-1512
45. Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, Dammacco F (2002) Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11:103-118
46. Van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH (1999) Cremophor EL causes (pseudo-) nonlinear pharmacokinetics of paclitaxel in patients. Br J Cancer 81(2):330-335